Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma

Ziad A Audat1*, Mahmoud H. Hajyousef2, Mohammad D. Fawareh3, Khaldoon M. Alawneh2, Mohannad A. Odat4, Mohammad M. Barbarawi2, Ali A. Alomari2, Rami A. Jahmani2, Mohammad A. Khatatbeh2 and Mohammed A. Assmairan2

Abstract

Background: This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients.

Methods: We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS).

Results: Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group).

Conclusion: Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.

Keywords: Multiple myeloma, Vertebral augmentation, Vertebroplasty, Kyphoplasty, Chemotherapy, Radiotherapy, Spine, Outcomes

Background

Multiple myeloma is accumulation of malignant plasma cell in the bone marrow leading to impaired blood cell formation and multiple lytic lesions in the skeleton. The incidence of bone involvement is about 70–100% while vertebral column is about 60% [1–3]. Bone becomes weak and easy to fracture, which may cause pain in the bone and inability to use the limb. In the spine, fractured vertebra causes pain, kyphotic or kyphoscoliotic deformity, compression of the spinal cord or cauda equina in addition to the general symptoms of multiple myeloma [1, 3].

General treatment of the disease includes radiotherapy, chemotherapy and bisphosphonate to decrease bone resorption in addition to analgesia, bed rest and bracing to treat pathological fractures [1]. Minimally-invasive vertebroplasty and balloon kyphoplasty are used as local treatment of the vertebral lesions to decrease pain and prevent or treat deformities [3–5]. Vertebroplasty is insertion of bone cement (polymethylmethacrylate) inside the vertebral body using pedicle cannula unilaterally or bilaterally while balloon kyphoplasty is insertion of balloon tamps through pedicle cannulae to reduce the height of the vertebra, realign the sagittal plane and create a cavity for bone cement [6–8]. Many studies were concentrating on multilevel vertebroplasty and kyphoplasty...
to treat multiple myeloma, but not more than 6 and 8 levels [9, 10].

At our hospital, we used vertebral augmentation in the management of multiple myeloma in a different way. We perform multilevel vertebral augmentation for all vulnerable vertebrae; thoracic, lumbar and sometimes the first sacral vertebra. Our practice is to not wait until the vertebra collapsed as a cause of the tumor, which may lead to neurological sequelae. As such, the following prospective study evaluated the outcomes of our multiple myeloma patients who underwent multilevel vertebral augmentation in addition to conventional therapy.

**Methods**

This is a prospective study of effectiveness of the addition of vertebral augmentation to conventional chemotherapy and radiotherapy in treating multiple myeloma patients. Our main aims were to prevent spinal column collapse, back deformity, neurological deficits, minimize pain and decrease general morbidities.

We treated 27 patients diagnosed with multiple myeloma at our institution that were newly diagnosed with more than 3 years follow-up. All patients had back pain without neurological deficits. All patients’ demographic data were extracted from the medical charts, consisting of age, gender, presenting symptoms, and follow-up period. Imaging studies included plain x-ray and magnetic resonance image (MRI) at the time of diagnosis (Figs. 1, 2, 3 and 4). The patients had histological diagnosis with bone marrow biopsy. The involved vertebra included lesions in the thoracic, lumbar, sacral vertebrae and cervical in one patient (C6 and C7). Mild kyphosis was seen in half of the patients. Consent form was signed by patients and Institutional Review Board (IRB) approval was obtained.

All patients received conventional chemotherapy and radiotherapy according to standard protocols of the hematology oncology. Patients were then were randomly categorized into two groups:

- **Group I:** 13 patients were treated by conventional treatment (i.e. chemotherapy and radiotherapy) (Table 1).
- **Group II:** 14 patients; 206 vertebrae, number of vertebrae ranged between 10 and 16 (mean: 14.7); were treated by vertebral augmentation in addition to conventional therapy (five patients with chemotherapy and radiotherapy and nine patients with chemotherapy) (Table 1). One patient needed radiotherapy post augmentation.

Vertebral bodies were augmented from the third thoracic (T3) to first sacral vertebrae (S1), all vertebrae were augmented if they were fractured or vulnerable to fracture whatever the size of the lesion. Vertebral augmentation was done under general anesthesia in the operation room under fluoroscope control. All levels for single patient were done at the same session. Balloon kyphoplasty and cement injection was used to restore the height of collapsed vertebra. Two balloons were used for each level. Transpedicular
technique was used for vertebrae below T8 and extrapedi-
cular for T8 and above. Vertebroplasty was used for non-
collapsed vertebrae by inserting working cannula and injec-
tion of bone cement. We used a transpedicular technique
for vertebrae below T8 and extrapedicular for T8 and
above, unilateral working cannula for T9 and above and bi-
lateral for T10 and below (Figs. 5 and 6). Patients were ob-
served at surgical flour for one postoperative day then
transferred to the hematology ward or discharged, then
followed-up at the outpatient clinic.
Patients who had spinal canal extension or spinal cord compromise, cauda equine compression, late-stage disease and patients who are previously underwent spinal surgery were excluded. International scoring and questionnaire systems consisting of the Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS) were used to evaluate the clinical and radiological results. The patients were evaluated clinically and radiographically on discharge-day, 6, 12, 24 and 36 months.

Statistically, we used SPSS version 20 (Chicago, IL, USA) to evaluate the results. Levene’s test for equality of variances was used to evaluate patients at each follow-up interval. This test gives mean values, standard deviation and $p$-value. Test of between-subjects effect, transformed variables: Average using ANOVA Method to evaluate the end results.

**Results**

We treated 27 patients, whom were recently diagnosed with multiple myeloma. There were 13 patients in group I (conventional treatment) and 14 patients in group II ($n = 206$ vertebrae, vertebral augmentation group). Mean age for group I was 58.2 years, mean follow-up was 36 months and

| Table 1 Demographic and clinical characteristics of patients according to method of treatment |
|---------------------------------|---------------|------------------|
| Number of patients              | 13            | 14               |
| Age (years)                     | 39–78 (Mean: 58.15, SD: 12.3) | 34–74  (Mean: 58.86, SD: 11.99) |
| Sex (Male : Female)             | 9:4           | 6:8              |
| Back Pain                       | All patients | All patients     |
| Neurological Deficit            | None          | None             |
| Treatment                       | Chemo and Radiotherapy = 7 | Vertebroplasty and Kyphoplasty |
|                                | Chemotherapy = 6 | Two hundred six vertebrae (one patient 10 v, one patient 12 v, three patients 14 v, two patients 15, and seven patients 16 vertebrae) in addition to Chemotherapy or Chemo and Radiotherapy |
male to female ratio was 9:4. For group II, the mean age was 58.9 years, the mean follow-up was 36 months and male to female ratio was 6:8. There was no significant statistical difference in the age between two groups as shown in Table 1.

Four patients (30.8%) of group I died between 7 and 11 months after diagnosis: three patients due to advanced disease and one by acute pneumonia. Four patients (28.6%) of group II died: one died at day of surgery by acute lung embolism and three died 18–24 months after surgery due to advanced disease and severe pneumonia (Table 2).
There were few intraoperative complications in group II. Cement leak inside the spinal canal with no significant neurological compromise or deficits occurred in one patient and intravascular leak in a small vessel was seen in two patients (Figs. 5 and 6). Bone cement didn’t affect chemotherapy or radiotherapy.

Oswestry Disability Index, Stanford score and the Spinal Instability Neoplastic Score values were nearly equal in both groups before treatment. ODI of group I was 31.9 (SD = 63.8%) with SD = 8.34 and of group II was 32.2 (66.4%) with SD = 5.98 (p = 0.418). SS of group I was 4.3 (SD = 2.6) and of group II was 4.6 (SD = 2.9) (p = 0.039). SINS of group I was 13.8 (SD = 2.9) and of group II was 12.8 (SD = 2.9) (p = 0.482).

At 6 months-follow up, group II value improved, ODI mean values were 32.5 (64.9%) and SD = 10.92) and 23.14 (66.4%) and SD = 8.49) for group I and II, respectively (p = 0.036). The SS value was 5.26 (SD = 2.9) for group I and 7.18 (SD = 1.39) for group II (p = 0.05). SINS was 12.85 (SD = 2.79) for group I and 7.15 SD 3.24 for group II (p = 0.449).

At 1 year follow-up, group I score values showed more improvement. ODI value for group I was 28.4 (56.8%) with SD = 8.79 and for group II was 21.4 (42.8%) with SD = 9.24 (p = 0.874). The SS value for group I was 5.28 with SD 2.88 and for group II was 7.52 with SD 1.48 (p = 0.012). SINS value for group I was 12.85 with SD 2.79 and for group II was 7.23 with SD 3.37 (p = 0.526).

At 2 years follow-up, ODI for group I was 28.42 (56.8%) with SD 8.79 and for group II was 21.43 (42.6%) with SD 9.24 (p = 0.874). The SS for group I was 5.40 with SD 2.83 and for group II was 7.68 with SD 1.56 (p = 0.047). SINS value for group I was 12.75 with SD 2.67 and for group II was 7.31 with SD 3.43 (p = 0.278).

At 3 years follow-up, ODI for group I was 29.17 (58.34%) with SD = 9.37 and for group II was 21.43 (42.86%) with SD 9.931 (p = 0.840). The SS mean value for group I was 5.27 with SD 2.94 and for group II was 7.83 with SD 1.64 (p = 0.940). SINS mean value for group I was 12.58 with SD 2.75 and for group II was 7.36 with SD = 3.72 a (p = 0.121).

At the end of the study (3 years), we used test of between-subjects effect, transformed variables: average using ANOVA method to compare the end results of each group. ODI and SINS showed significant difference between two groups (p = 0.047 and p = 0.002) with less significant difference by using SS (p = 0.039). All group II were freely mobile except one who used a cane when walk. All patients were back pain free except three, who had number of exacerbations of pain that may be attributed to disc disease or fracture of vertebral end plate over bone cement. All patients had preserved vertebral height and sagittal balance except for one who had history of inter-scapular pain 4 years after surgery and x-rays showed mild loss of height of T4 around the bone cement which was insignificant as compared to three patients of group I who became bedridden due to vertebral fractures with involvement of the spinal canal.
Discussion

This is was a prospective study to compare two groups of multiple myeloma patients who were treated at our institute. Group I was treated with conventional therapy and group II with multilevel vertebral augmentation in addition to conventional therapy. We couldn’t find any similar studies in the literature doing the same comparison. Most of previous studies involving multiple myeloma discussed mixed population of malignancy and were not focused such a disease. Few studies that focused on multiple myeloma treated only the fractured vertebra and showed similar results of our study [9, 11–17]. Our results showed that the addition of vertebral augmentation had better improvement in the outcome, both subjective and objective. The best rates of scores improvement were seen during the first 6 months. After that, improvement rate decreased with time, whereby group II showed better results as demonstrated in Figs. 7, 8 and 9.

The $p$-values (Levene’s test) of scores at each interval of follow-up is shown in Table 3. $P$-value of ODI was 0.316 at 6 moths and increase to 0.87 at all interval-follow up, which was considered insignificant. $P$-values of SS were ≤0.05 at all follow up periods, which were considered significant. $P$-value of SINS was 0.45 and decreased after 2 years to reach 0.12, which is more significant than ODI. At the end of study, $p$-value (by using ANOVA test) of ODI, SS scores, and SINS were 0.047, 0.180 and 0.002, respectively, which were statistically significant. This means that back pain, mobility, kyphotic deformity due to vertebral collapse and sagittal balance were improved. Most patients of group II became ambulating and totally pain free. As compared to none of group I were pain free and half of them were ambulating with aid.

In the literature review addressing previous studies discussing multilevel vertebral augmentation, we found that most of them were dealing with less than eight levels and were performed in more than one surgical session [9, 18]. Two case reports were found with multilevel vertebral augmentation. The first one was used to treat newly adjacent level fractures in a patient who was treated for osteoporotic fracture [19]. The second case was treated for multiple osteoporotic fractures that occurred at different times after vertebroplasty in a patient with chronic liver disease [20].

In our study, all the patients had the same disease, were treated by the same hematologist, all procedures were done by the same spine surgeon and evaluated by independent physicians. In group II, 14 patients (206 vertebrae), who underwent vertebral augmentation, the procedures were done at same session for all involved vertebra for single patient. This decreased the need and risk of repetitive anesthesia, although increased the operative time and radiological exposure. We did several measures to decrease surgical time and radiological exposure.

The $p$-value (Levene’s test) of scores at each interval of follow-up is shown in Table 3. $P$-value of ODI was 0.316 at 6 moths and increase to 0.87 at all interval-follow up, which was considered insignificant. $P$-values of SS were ≤0.05 at all follow up periods, which were considered significant. $P$-value of SINS was 0.45 and decreased after 2 years to reach 0.12, which is more significant than ODI. At the end of study, $p$-value (by using ANOVA test) of ODI, SS scores, and SINS were 0.047, 0.180 and 0.002, respectively, which were statistically significant. This means that back pain, mobility, kyphotic deformity due to vertebral collapse and sagittal balance were improved. Most patients of group II became ambulating and totally pain free. As compared to none of group I were pain free and half of them were ambulating with aid.

In the literature review addressing previous studies discussing multilevel vertebral augmentation, we found that most of them were dealing with less than eight levels and were performed in more than one surgical session [9, 18]. Two case reports were found with multilevel vertebral augmentation. The first one was used to treat newly adjacent level fractures in a patient who was treated for osteoporotic fracture [19]. The second case was treated for multiple osteoporotic fractures that occurred at different times after vertebroplasty in a patient with chronic liver disease [20].

In our study, all the patients had the same disease, were treated by the same hematologist, all procedures were done by the same spine surgeon and evaluated by independent physicians. In group II, 14 patients (206 vertebrae), who underwent vertebral augmentation, the procedures were done at same session for all involved vertebra for single patient. This decreased the need and risk of repetitive anesthesia, although increased the operative time and radiological exposure. We did several measures to decrease surgical time and radiological exposure.
Table 3 Postoperative intervals in relation to outcome scores

| Outcome Score | 6 months | 1 year | 2 years | 3 years |
|---------------|----------|--------|---------|---------|
| ODI           | 0.316    | 0.874  | 0.874   | 0.87    |
| SS            | 0.050    | 0.012  | 0.047   | 0.04    |
| SINS          | 0.449    | 0.526  | 0.278   | 0.121   |

Note, T-tailed p-value of each follow-up interval and test of between-subjects effect ODI Oswestry Disability Index, SS Stanford Score, SINS Spinal Instability Neoplastic Score

exposure, inserting a working cannula directly (eliminating introducing cannula and K wire need), inserting multiple cannulas at the same time and using unilateral cannula at T9 and above. In addition, there was no significant statistical difference of mortality rate between the two groups.

Conclusion
Multilevel vertebral augmentation in addition to conventional therapy showed superior results as compared with conventional therapy alone. It relieves pain, preserves vertebral height, sagittal balance and improves mobility of the patients. There was no significant difference of mortality rates between the two groups, but there was significant improvement of morbidity rates. The limitation of this study was the small sample size and variable follow-up periods. Larger, prospective studies are needed to further assess the outcome of such treatment modalities in multiple myeloma patients.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. IRB (Institutional Research Committee) of Jordan University of Sciece & Technology agreement number 218-2014 was obtained.

Authors’ contributions
ZA Corresponding author, participated in study design, review of the literature and patient information collection. MH Participated in study design and pre and postop medical management. MF Participated in study design and review of literature. KA Participated in study design and pre and postop medical management. MO Participated in study design and statistics. MB Participated in study design and review of literature. AA Participated in study design. RJ Participated in patient evaluation and study design. MK Participated in data collection and statistics. MA Participated in data collection and statistics.

Competing interests
The authors declare that they have no competing interests.

Author details
1Orthopedic Department, Jordan University of Science & Technology, King Abdullah University Hospital, Irbid 22110, Jordan. 2King Abdullah University Hospital, Amman-Ramtha Road, Irbid 22110, Outside of the US, Jordan. 3Ibn Alhaytham Hospital, Tela’ Al Ali, Amman 11953, Outside of the US, Jordan. 4Jordanian Royal Medical Services, King Abdullah the second, Amman 11822, Amman, Jordan.

References
1. La Maida GA, Sala F, Callea G, et al. Efficacy of unipedicular balloon kyphoplasty for treatment of multiple myeloma vertebral lesions. Asian Spine J. 2011;5:162–8.
2. Locouvet FE, Vande Berg BC, Maldague BE, et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology. 1997;204:195–9.
3. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol. 2002;20:2382–7.
4. Lavanga A, Guamieri G, Muto M. Medical therapy and multilevel vertebroplasty in osteoporotic when and why. Neuroradiol J. 2010;23:244–8.
5. Lane J, Hong R, Koob J, et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Rel Res. 2004;426:49–53.
6. Jensen ME, Evans AJ, Mathis JM, Killmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral compression fractures: technical aspects. Am J Neuroradiol. 1997;18:907–904.
7. Galibert P, Daradom H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie. 1987;33:166–8.
8. McArthur N, Kasprzak C, Baier M, et al. 1150 kyphoplasties over 7 years: indications, techniques, and intraoperative complications. Orthopedics. 2009;32:90.
9. Malii L, Filippiadis DK, Brountzos EN, et al. Clinical outcome and safety of multilevel vertebroplasty: clinical experience and results. Cardiovasc Intervent Radiol. 2013;36:183–91.
10. Katonis P, Hadjianavou A, Souvatzi X, et al. Respiratory effects, hemodynamic changes and cement leakage during multilevel cement balloon Kyphoplasty. Eur Spine J. 2012;21:1860–6.
11. McDonald RJ, Trout AT, Gray LA, et al. Vertebraloplasty in multiple myeloma: outcomes in a large patient series. AJNR Am J Neuroradiol. 2008;29:642–8.
12. Masala S, Anselmetti GC, Marcia S, et al. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J Spinal Disc Tech. 2008;21:344–8.
13. Dunn J. Percutaneous vertebroplasty in the management of a patient with malignant pain and associated osteolytic compression fractures. Curr Pain Headache Rep. 2002;6:436–43.
14. Yang Z, Xu J, Sang C. Clinical studies on treatment of patients with malignant spinal tumors by percutaneous vertebroplasty under guidance of digital subtraction angiography [in Chinese]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2006;20:999–1003.
15. Ryska P, Rehak S, Odraika F, et al. Role of percutaneous vertebroplasty and kyphoplasty in the treatment of oncology disorders of the spine [in Czech]. Gas Lek Cesk. 2006;145:804–9.
16. O’Brien J, Brennan D, Taylor D, et al. Percutaneous vertebroplasty–initial clinical experience in osteoporotic and myelomatus compression fractures. Ir J Med Sci. 2006;175:50–3.
17. Bartolozi B, Nozzoli C, Pandolfo C, et al. Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma. Eur J Haematol. 2006;76:180–1.
18. Graya LA, Ehezthami Rada A, et al. Efficacy of percutaneous vertebroplasty for multiple synchronous and metachronous vertebral compression fractures. AJNR Am J Neuroradiol. 2009;30:318–22.
19. Kim HW, Song JW, et al. Extreme multi-level percutaneous vertebroplasty for newly developed multiple adjacent compression fractures. J Korean Neurosurg Soc. 2009;45:278–80.
20. Karatoprak O, Camurdan K, et al. Multiple-level cement vertebroplasty in patients with vertebral compression fractures from osteodystrophy in chronic liver disease. Acta Orthop Belg. 2008;74:566–8.

Received: 10 January 2016 Accepted: 8 December 2016
Published online: 29 December 2016